Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.59 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.50 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.47 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.47 |
| ▸ | PLAU | P00749 | 1/20 | 0.46 |
| ▸ | TTR | P02766 | 1/20 | 0.45 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.44 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.43 |
| ▸ | PNMT | P11086 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4698595 | 0.98 | TSHR (0.57) | TSHREPHX2NR1H4MAPTALDH1A1 | |
| SCHEMBL8834695 | 0.86 | SRD5A2 (0.48) | TSHREPHX2NR1H4ALDH1A1NR4A2 | |
| SCHEMBL9185167 | 0.85 | TSHR (0.55) | TSHREPHX2NR1H4MAPTALDH1A1 | |
| Hydrochloric Acid SCHEMBL8834080 | 0.85 | SRD5A2 (0.47) | TSHREPHX2NR1H4ALDH1A1NR4A2 | |
| SCHEMBL27722327 | 0.85 | SLC6A4 (0.47) | TSHRPLAUPNMTHTR7 | |
| SCHEMBL7450888 | 0.85 | TSHR (0.59) | TSHREPHX2MAPTALDH1A1NR4A2 | |
| Hydrochloric Acid SCHEMBL3656362 | 0.84 | TSHR (0.53) | TSHREPHX2NR1H4MAPTALDH1A1 | |
| Hydrochloric Acid SCHEMBL7352172 | 0.83 | TSHR (0.57) | TSHREPHX2MAPTALDH1A1NR4A2 | |
| SCHEMBL6659614 | 0.82 | TSHR (0.61) | TSHREPHX2NR1H4MAPTALDH1A1 | |
| SCHEMBL17198001 | 0.82 | TSHR (0.61) | TSHREPHX2NR1H4MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3184553-B1 | DERIVATIVE OF HYALURONIC ACID MODIFIED WITH AMINO-CARBOXYLIC ACID | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2019-05-01 | — | — | EP | disclosed |
| EP-2682409-B1 | DERIVATIVE OF HYALURONIC ACID MODIFIED WITH AMINO-CARBOXYLIC ACID | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2017-07-05 | — | — | EP | disclosed |
| EP-3184553-A1 | DERIVATIVE OF HYALURONIC ACID MODIFIED WITH AMINO-CARBOXYLIC ACID | Chugai Seiyaku Kabushiki Kaisha (JP) | 2017-06-28 | — | — | EP | disclosed |
| US-9243077-B2 | Derivative of hyaluronic acid modified with amino-carboxylic acid | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-01-26 | — | — | US | disclosed |
| CN-102746214-A | Novel indoline compounds | FOURNIER LAB SA | 2012-10-24 | — | — | CN | disclosed |
| US-7465811-B2 | Indoline compounds | LABORATOIRES FOURNIER S.A. (FR) | 2008-12-16 | — | — | US | disclosed |
| US-20080275026-A1 | Benzamide derivatives as oxytocin agonists and vasopressin antagonists | FERRING B.V. | 2008-11-06 | — | — | US | disclosed |
| US-7407949-B2 | Benzamide derivatives as oxytocin agonists and vasopressin antagonists | FERRING B.V. (NL) | 2008-08-05 | — | — | US | disclosed |
| US-20080119465-A1 | Novel Indoline Compounds | LABORATORIES FOURNIER S.A. (FR) | 2008-05-22 | — | — | US | disclosed |
| CN-101184731-A | Indoline compounds | FOURNIER LAB SA (FR) | 2008-05-21 | — | — | CN | disclosed |
| WO-2003016316-A1 | DIAZACYCLOALKANES AS OXYTOCIN AGONISTS | FERRING B.V. (NL) | 2003-02-27 | — | — | WO | disclosed |
| WO-2003000692-A2 | OXYTOCIN AGONISTS | FERRING BV (NL) | 2003-01-03 | — | — | WO | disclosed |
| US-6403578-B1 | ANTICOAGULANTS, CARDIOVASCULAR DISORDERS | SMITHKLINE BEECHAM CORPORATION | 2002-06-11 | — | — | US | disclosed |
| CN-1215054-A | Bychclic fibrinogen antagonists | SMITHKLINE BEECHAM CORP (US) | 1999-04-28 | — | — | CN | disclosed |
| CN-1041921-C | Bicyclic fibrinogen antagonists | SMITHKLINE BEECHAM CORP (US) | 1999-02-03 | — | — | CN | disclosed |
| EP-0674623-A1 | BICYCLIC FIBRINOGEN ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1995-10-04 | — | — | EP | disclosed |
| EP-0342931-B1 | Method for the production of human tissue type plasminogen activator | MITSUI TOATSU CHEMICALS (JP) | 1994-07-20 | — | — | EP | disclosed |
| WO-1994014776-A2 | BICYCLIC FIBRINOGEN ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1994-07-07 | — | — | WO | disclosed |
| US-5151359-A | P-aminomethylbenzoic acid in a cell culture, incubation | MITSUI TOATSU CHEMICALS INCORPORATED (JP) | 1992-09-29 | — | — | US | disclosed |
| EP-0342931-A1 | Method for the production of human tissue type plasminogen activator | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1989-11-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275026-A1 | Benzamide derivatives as oxytocin agonists and vasopressin antagonists | AVPR1A, AVPR2, AVPR1B | TSHR 139/4885EPHX2 4187/4885NR1H4 301/4885 |
| US-20080119465-A1 | Novel Indoline Compounds | GPR119, INSR, IRS1 | TSHR 681/4885EPHX2 3674/4885NR1H4 493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.